Evaluation of the Safety, Tolerability, and Efficacy of MDGN-002 in Adults With Moderate to Severe Active Crohn's Disease
Status:
Recruiting
Trial end date:
2021-10-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1b, open-label, dose-escalation, signal-finding, multi-center study. The
study will evaluate the safety, tolerability, pharmacokinetics and short-term efficacy of
MDGN-002 in adults with moderate to severe, active Crohn's disease who have previously failed
anti-tumor necrosis factor alpha (anti-TNFα) treatment.
Phase:
Phase 1
Details
Lead Sponsor:
Aevi Genomic Medicine Aevi Genomic Medicine, LLC, a Cerecor company